<DOC>
	<DOCNO>NCT01614431</DOCNO>
	<brief_summary>This study intend verify interference N acetyl cysteine progression chronic kidney disease patient Nephropathic Cystinosis .</brief_summary>
	<brief_title>N Acetyl Cysteine Cystinosis Patients</brief_title>
	<detailed_description>Patients Nephropathic Cystinosis increase oxidative stress go end-stage renal disease , even step treatment do . Therefore , study conduct verify interference stress oxidative progression renal disease use oxidant drug , N acetyl cysteine ( NAC ) . The investigator select patient good compliance treatment . In patient investigator evaluate serum creatinine , creatinine clearance estimate Schwartz Formula , cystatin C marker oxidative stress , TBARS ( thiobarbituric acid substance ) . The variable analyze 6 month introduction NAC three month NAC .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Cystinosis</mesh_term>
	<mesh_term>Acetylcysteine</mesh_term>
	<mesh_term>N-monoacetylcystine</mesh_term>
	<criteria>cystinosis patient age 18 year good compliance treatment Chronic Kidney Disease 1 4 accord KDOQI patient CKD stage 5</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>renal function</keyword>
	<keyword>N acetyl cysteine</keyword>
	<keyword>Cystinosis patient</keyword>
</DOC>